Literature DB >> 34137224

Construction of point mutation rabbits using CRISPR/Cas9.

Kunning Yan1, Ting Zhang1, Yiwen Zha1, Jingyan Liang1, Yong Cheng1.   

Abstract

To establish a rabbit model of proprotein convertase subtilisin/kexin type9 () point mutation with CRISPR/Cas9 gene editing technique. According to the PubMed gene protein data, the PCSK9 protein functional regions of human and rabbit were analyzed by Blast. The 386S (Ser) amino acid functional region of human gene was homologous to the 485S of rabbit gene. Three small guide RNAs and one single-stranded donor oligonucleotide were designed according to the 485S base substitution position and sequence analysis of rabbit gene. The synthetic small guide RNAs, Cas9 mRNA and single-stranded donor oligonucleotide were co-injected into the cytoplasm of rabbit fertilized eggs and the embryos were transferred into the pregnant rabbits. PCR, TA cloning and off-target analysis were performed on the F0 rabbits to identify whether the PCSK9 mutation was successful. Fifteen F0 rabbits were obtained. The sequencing results showed that one of them was PCSK9 point mutation homozygote and two of them were PCSK9 point mutation heterozygotes, and the mutation could be stably inherited. The rabbit model of PCSK9 point mutation was successfully constructed by CRISPR/Cas9 technique, which provides an animal model for exploring the molecular mechanism of impaired PCSK9 function and developing reliable and effective diagnosis and treatment measures.

Entities:  

Keywords:  Animal model; CRISPR/Cas9; New Zealand rabbit; Point mutation; Proprotein convertase subtilisin/kexin type 9

Mesh:

Substances:

Year:  2021        PMID: 34137224      PMCID: PMC8710267          DOI: 10.3724/zdxbyxb-2021-0133

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  19 in total

Review 1.  Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.

Authors:  Chang Liu; Li Zhang; Hao Liu; Kun Cheng
Journal:  J Control Release       Date:  2017-09-11       Impact factor: 9.776

2.  Prevention of cardiovascular disease: Much more is needed.

Authors:  Guy G De Backer
Journal:  Eur J Prev Cardiol       Date:  2018-04-25       Impact factor: 7.804

Review 3.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

Review 4.  Role of PCSK9 in lipid metabolism and atherosclerosis.

Authors:  Xiao-Long Lin; Le-Le Xiao; Zhi-Han Tang; Zhi-Sheng Jiang; Mi-Hua Liu
Journal:  Biomed Pharmacother       Date:  2018-05-11       Impact factor: 6.529

5.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

6.  Plasma PCSK9 preferentially reduces liver LDL receptors in mice.

Authors:  Aldo Grefhorst; Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Lipid Res       Date:  2008-03-19       Impact factor: 5.922

7.  Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

Authors:  Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Biol Chem       Date:  2007-05-29       Impact factor: 5.157

8.  CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.

Authors:  Li Xu; Ki Ho Park; Lixia Zhao; Jing Xu; Mona El Refaey; Yandi Gao; Hua Zhu; Jianjie Ma; Renzhi Han
Journal:  Mol Ther       Date:  2015-10-09       Impact factor: 11.454

Review 9.  PCSK9: A novel inflammation modulator in atherosclerosis?

Authors:  Zhi-Han Tang; Tao-Hua Li; Juan Peng; Jie Zheng; Ting-Ting Li; Lu-Shan Liu; Zhi-Sheng Jiang; Xi-Long Zheng
Journal:  J Cell Physiol       Date:  2018-09-24       Impact factor: 6.384

10.  Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.

Authors:  Matthew J Bottomley; Agostino Cirillo; Laura Orsatti; Lionello Ruggeri; Timothy S Fisher; Joseph C Santoro; Richard T Cummings; Rose M Cubbon; Paola Lo Surdo; Alessandra Calzetta; Alessia Noto; Jennifer Baysarowich; Marco Mattu; Fabio Talamo; Raffaele De Francesco; Carl P Sparrow; Ayesha Sitlani; Andrea Carfí
Journal:  J Biol Chem       Date:  2008-11-10       Impact factor: 5.157

View more
  1 in total

Review 1.  Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies.

Authors:  Meidi Utami Puteri; Nuriza Ulul Azmi; Salbiah Ridwan; Muhammad Iqbal; Tresni Fatimah; Tri Diana Puspita Rini; Mitsuyasu Kato; Fadlina Chany Saputri
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.